Next Generation Synthetic Influenza Vaccine to be Developed
HUNTINGTON, W.Va.--(BUSINESS WIRE)--Vandalia Research has been awarded a $1.04M contract with the US Department of Defense, titled, Flu Vaccine Technology Program. This program will focus on the scale-up and pre-clinical development of a pandemic flu vaccine manufactured by Vandalia's proprietary large scale PCR process using the Triathlon bioreactor. The contract is scheduled to run for 18 months and will be performed in collaboration with Dr. Richard Heller of the Frank Reidy Research Center for Bioelectrics at Old Dominion University in Norfolk, Virginia and Dr. Colleen Jonsson, Director, Center for Predictive Medicine at the University of Louisville.
The funds I obtained will help protect against pandemic outbreaks, keeping our families and our communities safer, and will create useful platforms for American industry to launch additional life-saving and sustaining products .
Vandalia Research is answering the national call to action for innovation in our manufacturing sector. As modern-day pioneers, blazing new trails with cutting-edge methodologies to keep us competitive and secure in the world, they strengthen our communities with job creation, said U.S. Rep. Nick Rahall (D-WV). The funds I obtained will help protect against pandemic outbreaks, keeping our families and our communities safer, and will create useful platforms for American industry to launch additional life-saving and sustaining products .
Rahall secured the funding for Department of Defense (DoD) technology development by Vandalia Research in the FY 2010 Department of Defense Appropriations Act. Through this funding, the program would be able to create three to five highly skilled jobs immediately with the potential for additional jobs as the research progresses.
This contract lends validation to our efforts to develop a scalable new method to rapidly develop and manufacture vaccines, stated Derek Gregg, CEO of Vandalia Research. We would like to thank Congressman Rahall and his staff for aiding in our receipt of this contract, continues Mr. Gregg.
Vandalia Research is exhibiting this week at the BIO2011 Convention in Washington, DC as part of the West Virginia pavilion (Booth 2443).
About Vandalia Research, Inc.
Vandalia Research is the first company to successfully scale-up the polymerase chain reaction (PCR) from an analytical tool to a viable large-scale manufacturing process, enabling DNA sequences to be made more efficiently and cost-effectively. Vandalia is helping companies develop vaccines, diagnostics, bio-agriculture, and gene therapies for existing and emerging markets, and is well-positioned as a key supplier for the research, clinical, and commercialization stages of these products.
About the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases.
The mission of the Center for Predictive Medicine is to improve human health by conducting basic research that translates to the development of diagnostic biomarkers, vaccines and therapeutics for pathogens requiring BSL-3 containment. In support of these activities, the Center manages the recently opened Regional Biocontainment Laboratory, constructed and equipped through funding from National Institutes for Health and the University of Louisville. The facility provides state-of-the-art biosafety level 3 and advanced imaging technologies for the conduct of research for internal and external University and biotechnology partners.
About the Frank Reidy Research Center for Bioelectrics at Old Dominion University.
The Frank Reidy Research Center for Bioelectrics (CBE) at Old Dominion University is a global leader in advancing the field of bioelectrics. The mission of the Center for Bioelectrics is to increase scientific knowledge and understanding of the interaction of electromagnetic fields and ionized gases with biological cells and to apply this knowledge to the development of medical diagnostics, therapeutics, and environmental decontamination. Old Dominion University is a state-assisted, Carnegie doctoral/research institution enrolling more than 24,000 students, including 6,000 graduate students, both in Norfolk and at numerous distance sites throughout Virginia and beyond. The University's main campus is in Norfolk, one of the cities making up the Hampton Roads region of Southeastern Virginia, a major seaport and resort area with a population in excess of 1.5 million.